Liu Gene-Fu F, Bair Ryan J, Bair Eric, Liauw Stanley L, Koshy Matthew
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, Illinois, United States of America.
Departments of Endodontics and Biostatistics, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States of America.
PLoS One. 2014 Jan 9;9(1):e82642. doi: 10.1371/journal.pone.0082642. eCollection 2014.
PURPOSE/OBJECTIVES: To determine if intensity modulated radiation therapy (IMRT) in the post-operative setting for gastric cancer was associated with reduced toxicity compared to 3D conformal radiation therapy (3DCRT).
MATERIALS/METHODS: This retrospective study includes 24 patients with stage IB-IIIB gastric cancer consecutively treated from 2001-2010. All underwent surgery followed by adjuvant chemoradiation. Concurrent chemotherapy consisted of 5-FU/leucovorin (n = 21), epirubicin/cisplatin/5FU (n = 1), or none (n = 2). IMRT was utilized in 12 patients and 3DCRT in 12 patients. For both groups, the target volume included the tumor bed, anastomosis, gastric stump, and regional lymphatics.
Median follow-up for the entire cohort was 19 months (range 0.4-8.5 years), and 49 months (0.5-8.5 years) in surviving patients. The 3DCRT group received a median dose of 45 Gy, and the IMRT group received a median dose of 50.4 Gy (p = 0.0004). For the entire cohort, 3-year overall survival (OS) was 40% and 3-year disease free survival (DFS) was 41%. OS and DFS did not differ significantly between the groups. Acute toxicity was similar. Between 3DCRT and IMRT groups, during radiotherapy, median weight lost (3.2 vs. 3.3 kg, respectively; p = 0.47) and median percent weight loss were similar (5.0% vs. 4.3%, respectively; p = 0.43). Acute grade 2 toxicity was experienced by 8 patients receiving 3DCRT and 11 receiving IMRT (p = 0.32); acute grade 3 toxicity occurred in 1 patient receiving 3DCRT and none receiving IMRT (p = 1.0). No patients in either cohort experienced late grade 3 toxicity, including renal or gastrointestinal toxicity. At last follow up, the median increase in creatinine was 0.1 mg/dL in the IMRT group and 0.1 mg/dL in the 3DCRT group (p = 0.78).
This study demonstrates that adjuvant chemoradiation for gastric cancer with IMRT to 50.4 Gy was well-tolerated and compared similarly in toxicity with 3DCRT to 45 Gy.
目的/目标:确定与三维适形放疗(3DCRT)相比,胃癌术后调强放疗(IMRT)是否能降低毒性。
材料/方法:这项回顾性研究纳入了2001年至2010年连续接受治疗的24例IB - IIIB期胃癌患者。所有患者均接受手术,随后进行辅助放化疗。同步化疗方案包括氟尿嘧啶/亚叶酸钙(n = 21)、表柔比星/顺铂/氟尿嘧啶(n = 1)或未进行化疗(n = 2)。12例患者采用IMRT,12例患者采用3DCRT。两组的靶区均包括肿瘤床、吻合口、胃残端和区域淋巴结。
整个队列的中位随访时间为19个月(范围0.4 - 8.5年),存活患者的中位随访时间为49个月(0.5 - 8.5年)。3DCRT组的中位剂量为45 Gy,IMRT组的中位剂量为50.4 Gy(p = 0.0004)。整个队列的3年总生存率(OS)为40%,3年无病生存率(DFS)为41%。两组之间的OS和DFS无显著差异。急性毒性相似。在3DCRT组和IMRT组之间,放疗期间,中位体重减轻分别为3.2 kg和3.3 kg(p = 0.47),中位体重减轻百分比相似(分别为5.0%和4.3%;p = 0.43)。接受3DCRT的8例患者和接受IMRT的11例患者出现急性2级毒性(p = 0.32);接受3DCRT的1例患者出现急性3级毒性,接受IMRT的患者无急性3级毒性(p = 1.0)。两个队列中均无患者出现晚期3级毒性,包括肾脏或胃肠道毒性。在最后一次随访时,IMRT组肌酐的中位增加值为每分升0.1毫克,3DCRT组为每分升0.1毫克(p = 0.78)。
本研究表明,胃癌辅助放化疗采用IMRT至50.4 Gy耐受性良好,毒性与采用3DCRT至45 Gy相似。